Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Suspended 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Breast Neoplasms 523Leukemia, Myeloid, Acute 499Neoplasms 381Carcinoma, Non-Small-Cell Lung 381Pancreatic Neoplasms 329Precursor Cell Lymphoblastic Leukemia-Lymphoma 319Multiple Myeloma 312Glioblastoma 311Melanoma 310Prostatic Neoplasms 293Leukemia 289Neoplasm Metastasis 284Brain Neoplasms 277Lymphoma 271Lung Neoplasms 270Recurrence 267Ovarian Neoplasms 247Colorectal Neoplasms 246Lymphoma, Non-Hodgkin 242Leukemia, Lymphocytic, Chronic, B-Cell 231Glioma 209Myelodysplastic Syndromes 208Lymphoma, Large B-Cell, Diffuse 186Carcinoma, Hepatocellular 173Lymphoma, Follicular 167Head and Neck Neoplasms 162Hodgkin Disease 160Lymphoma, Mantle-Cell 155Burkitt Lymphoma 154Sarcoma 150

Interventions

talazoparib 1olaparib 1CX 5461 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × OTHER × Metastatic Castration Resistant Prostate Cancer (mCRPC) × Clear all
NCT07621692 2026-06-02

Exploring Auger-Enhanced PSMA-Targeted Radioligand Therapy: A First-in-Taiwan Clinical Study of 161Tb-PSMA-I&T

National Taiwan University Hospital

Phase 1 Recruiting
12 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT03874884 2025-05-14

LuPARP

Peter MacCallum Cancer Centre, Australia

Phase 1 Active not recruiting
70 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

NCT05425862 2023-12-11

REPAIR

Peter MacCallum Cancer Centre, Australia

Phase 1 Suspended
48 enrolled
Genitourinary

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Data powered by HemOnc (CC BY 4.0) Colophon âš¡